Table 2 Baseline characteristics of the serum donors.
From: Lipidome profile predictive of disease evolution and activity in rheumatoid arthritis
Preclinical RA (n = 18) | Active RA (n = 42) | RA in SR (n = 19) | OA (n = 49) | P value | |
|---|---|---|---|---|---|
Female, n (%) | 15 (83.3%) | 37 (88.1%) | 16 (84.2%) | 43 (87.8%) | 0.941 |
Age (years) | 52.1 ± 9.8 | 56.6 ± 12.7 | 55.5 ± 9.2 | 54.7 ± 11.2 | 0.836 |
BMI, kg/m2 | 23.2 ± 2.4 | 22.7 ± 2.8 | 22.1 ± 2.4 | 23.1 ± 3.3 | 0.945 |
RA duration, yr | - | 8.9 ± 8.7 | 9.0 ± 9.9 | - | 0.955 |
RF-positive, n (%) | 15/18 (83.3) | 37/42 (88.1) | 13/19 (68.4) | - | 0.164 |
ACPA-positive, n (%) | 14/18 (77.8) | 31/35 (88.6) | 11/16 (68.8) | - | 0.118 |
Laboratory Findings | |||||
ESR, mm/h | 12.2 ± 13.1 | 28.4 ± 19.2 | 8.0 ± 6.9 | 7.6 ± 5.6 | <0.001 |
CRP, mg/dl | 0.2 ± 0.3 | 1.1 ± 1.1 | 0.2 ± 0.2 | 0.2 ± 0.5 | 0.004 |
Albumin, g/L | 4.4 ± 0.2 | 4.1 ± 0.4 | 4.2 ± 0.2 | 4.4 ± 0.2 | 0.633 |
Hemoglobin, g/L | 14.4 ± 6.2 | 12.5 ± 1.1 | 12.9 ± 1.2 | 13.5 ± 1.2 | 0.846 |
DAS28 | - | 4.7 ± 1.0 | 1.7 ± 0.7 | - | <0.001 |
MTX, n (%) | - | 26 (61.9%) | 15 (78.9%) | - | 0.309 |
HCQ, n (%) | - | 14 (33.3%) | 10 (52.6%) | - | 0.104 |
SSZ, n (%) | - | 5 (11.9%) | 3 (15.8%) | - | 0.705 |
LEF, n (%) | - | 14 (33.3%) | 10 (52.6%) | - | 0.208 |
Biologics, n (%) | - | 7 (16.7%) | 6 (31.6%) | - | 0.318 |
